A unique biomedical polymer that mimics natural cartilage and aids in smooth joint articulation and mobility.3

Unlike LRTI and Trapeziectomy, Cartiva® maintains the normal anatomy by sparing the trapezium and preserving joint height.

Cartiva SCI does not "burn a bridge" to excellent pain relief and successful functional outcomes, if a revision procedure is needed.2


Reduction in Pain1

VAS Pain Score

Cartiva pain reduction data

A substantial and clinically meaningful reduction in pain using the Visual Analog Scale (VAS) was observed for Cartiva patients at 12 months. 80% of Cartiva implant patients demonstrated a clinically meaningful reduction in pain from baseline at 12 months.1,4


QuickDASH Score1

Cartiva patients demonstrate improvement in QuickDASH score.

Cartiva QuickDash improvement data for hand

Functional activities were evaluated using the QuickDash. A substantial reduction (improvement) was observed in the mean QuickDash scores at 12 months. 94% of Cartiva implant patients demonstrated a clinically meaningful reduction in disability (improvement in function) from baseline at 12 months.1,5

Clinical Trials

  • A Prospective Study to Evaluate the Safety and Effectiveness of the Cartiva® Synthetic Cartilage Implant for CMC in the Treatment of First Carpometacarpal Joint Osteoarthritis
    View full study
  • Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)
    View full study


Clinical Trials

Download PDF Brochure

Cartiva® CMC Joint Surgical Procedure


Interested in offering Cartiva® to patients?

Fill out the form below for more details.

I'd like more information about Cartiva®
I'd like to schedule a demonstration


1 Data on file at Cartiva; n = 49 @ 12 months, GRIP Study.

2 Bainbridge L.C., et al. “A prospective, multicenter clinical trial to assess safety and efficacy of a synthetic cartilage implant for treatment of Eaton-Littler stage II/III first CMC joint osteoarthritis: Cartiva GRIP Trial.” BSSH Abstract. 2017 July 14; Abstract Ref 31911.

3 Oka M, Ushio K, Kumar P, Ikeuchi K, Hyon SH, Nakamura T, Fujita H. Development of artificial articular cartilage. Proc Inst Mech Eng H. 2000;214(1):59-68.

4 Dworkin RH, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.

5 Franchignoni, Franco, et al. “Minimal clinically important difference of the disabilities of the arm, shoulder and hand outcome measure (DASH) and its shortened version (QuickDASH).” journal of orthopaedic & sports physical therapy 44.1 (2014): 30-39.

Cartiva’s Synthetic Cartilage Implant is not approved for use in the 1st CMC joint in the United States. Currently only available for use in Europe and Canada.

© 2008-2019. All Rights Reserved
Company Reg. No: 6545496